PainReform Announces Closing of $4 Million Public Offering
April 18, 2024 14:19 ET
|
PainReform Ltd
TEL AVIV, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Announces Pricing of $4 Million Public Offering
April 16, 2024 08:00 ET
|
PainReform Ltd
TEL AVIV, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions
April 09, 2024 09:00 ET
|
PainReform Ltd
TEL AVIV, Israel, April 09, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy
April 02, 2024 08:30 ET
|
PainReform Ltd
TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Provides Year-End Business Update
March 01, 2024 08:00 ET
|
PainReform Ltd
Reports continued enrollment in the second part of the Phase 3 clinical trial in bunionectomy Remains on track to announce top-line data by mid-2024 TEL AVIV, Israel, March 01, 2024 (GLOBE...
PainReform to Present at the Microcap Conference in Atlantic City
January 22, 2024 08:30 ET
|
PainReform Ltd
TEL AVIV, Israel, Jan. 22, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief
January 03, 2024 08:30 ET
|
PainReform Ltd
TEL AVIV, Israel, Jan. 03, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds
December 26, 2023 18:00 ET
|
PainReform Ltd
TEL AVIV, Israel, Dec. 26, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Provides Business Update for the Third Quarter of 2023
November 15, 2023 16:05 ET
|
PainReform Ltd
TEL AVIV, Israel, Nov. 15, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File
September 11, 2023 08:30 ET
|
PainReform Ltd
Targeting to commence second part of Phase 3 clinical trial in mid-Q4 2023 Trial completion and results expected in mid-2024 TEL AVIV, Israel, Sept. 11, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd....